APO Research
Talk to an analyst

APO RESEARCH · REPORT

Artificial Blood Substitute

Artificial blood refers to artificial blood cells and their functional substitutes. Its function, as the name suggests, is to replace real human blood to meet people's demand for blood and make up for the current blood shortage.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Artificial blood refers to artificial blood cells and their functional substitutes. Its function, as the name suggests, is to replace real human blood to meet people's demand for blood and make up for the current blood shortage.

Selected research

Market Analysis & Forecast

Global Artificial Blood Substitute Market Analysis and Forecast 2026-2032

28 December 2025190 pages

Choose your research edition.

Industry ResearchArtificial Blood Substitute Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Artificial Blood Substitute Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Artificial Blood Substitute Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Artificial Blood Substitute Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Artificial Blood Substitute Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Artificial blood refers to artificial blood cells and their functional substitutes. Its function, as the name suggests, is to replace real human blood to meet people's demand for blood and make up for the current blood shortage.

Artificial blood substitutes are used as oxygen therapy agents for emergency resuscitation and disease treatment. They have very important practical significance in developing countries and field hospitals that lack blood and urgently need blood transfusion, lack refrigeration equipment, and even on the battlefield. At the same time they do have great potential in reducing the spread of infectious diseases and providing new options for religious people who refuse blood transfusions.

Despite the huge application prospects, these artificial blood products all face some common problems. In addition to the safety and efficacy to be verified by clinical trials, the current production scale still needs to be greatly increased, and the production cost needs to be greatly reduced to meet the future demand for artificial blood .

Read the full market overview

Report Includes

This report presents an overview of global market for Artificial Blood Substitute, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Artificial Blood Substitute, also provides the revenue of main regions and countries. Of the upcoming market potential for Artificial Blood Substitute, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Artificial Blood Substitute revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Artificial Blood Substitute market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Artificial Blood Substitute revenue, projected growth trends, production technology, application and end-user industry.

Artificial Blood Substitute Segment by Company

Aurum Biosciences Ltd.

HEMARINA SA

HbO2 Therapeutics

KaloCyte Inc.

SpheriTech Ltd.

NuvOx Pharma

Artificial Blood Substitute Segment by Type

Perfluorocarbon-based Oxygen Carrier (PFBOC)

Hemoglobin-based Oxygen Carrier (HBOC)

Artificial Blood Substitute Segment by Application

Military

Civil

Artificial Blood Substitute Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Artificial Blood Substitute market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Artificial Blood Substitute and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Artificial Blood Substitute.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Artificial Blood Substitute in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Artificial Blood Substitute company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Artificial Blood Substitute revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Artificial Blood Substitute Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Perfluorocarbon-based Oxygen Carrier (PFBOC) Major Player Table 3. Hemoglobin-based Oxygen Carrier (HBOC) Major Player Table 4. Global Artificial Blood Substitute Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Military Major Player Table 6. Civil Major Player Table 7. Artificial Blood Substitute Industry Trends Table 8. Artificial Blood Substitute Industry Drivers Table 9. Artificial Blood Substitute Industry Opportunities and Challenges Table 10. Artificial Blood Substitute Industry Restraints Table 11. Global Artificial Blood Substitute Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Artificial Blood Substitute Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Artificial Blood Substitute Market Share by Region (2021-2026) Table 14. Global Artificial Blood Substitute Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Artificial Blood Substitute Market Share by Region (2027-2032) Table 16. Global Artificial Blood Substitute Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Artificial Blood Substitute Revenue Market Share by Players (2021-2026) Table 18. Global Artificial Blood Substitute Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Artificial Blood Substitute Key Players Headquarters & Area Served Table 20. Global Artificial Blood Substitute Players, Product Type & Application Table 21. Global Artificial Blood Substitute Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Artificial Blood Substitute by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Artificial Blood Substitute Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Artificial Blood Substitute Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Artificial Blood Substitute Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Artificial Blood Substitute Revenue Market Share by Type (2021-2026) Table 28. Global Artificial Blood Substitute Revenue Market Share by Type (2027-2032) Table 29. Global Artificial Blood Substitute Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Artificial Blood Substitute Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Artificial Blood Substitute Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Artificial Blood Substitute Revenue Market Share by Application (2021-2026) Table 33. Global Artificial Blood Substitute Revenue Market Share by Application (2027-2032) Table 34. Aurum Biosciences Ltd. Company Information Table 35. Aurum Biosciences Ltd. Business Overview Table 36. Aurum Biosciences Ltd. Artificial Blood Substitute Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Aurum Biosciences Ltd. Artificial Blood Substitute Product Portfolio Table 38. Aurum Biosciences Ltd. Recent Development Table 39. HEMARINA SA Company Information Table 40. HEMARINA SA Business Overview Table 41. HEMARINA SA Artificial Blood Substitute Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. HEMARINA SA Artificial Blood Substitute Product Portfolio Table 43. HEMARINA SA Recent Development Table 44. HbO2 Therapeutics Company Information Table 45. HbO2 Therapeutics Business Overview Table 46. HbO2 Therapeutics Artificial Blood Substitute Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. HbO2 Therapeutics Artificial Blood Substitute Product Portfolio Table 48. HbO2 Therapeutics Recent Development Table 49. KaloCyte Inc. Company Information Table 50. KaloCyte Inc. Business Overview Table 51. KaloCyte Inc. Artificial Blood Substitute Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. KaloCyte Inc. Artificial Blood Substitute Product Portfolio Table 53. KaloCyte Inc. Recent Development Table 54. SpheriTech Ltd. Company Information Table 55. SpheriTech Ltd. Business Overview Table 56. SpheriTech Ltd. Artificial Blood Substitute Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. SpheriTech Ltd. Artificial Blood Substitute Product Portfolio Table 58. SpheriTech Ltd. Recent Development Table 59. NuvOx Pharma Company Information Table 60. NuvOx Pharma Business Overview Table 61. NuvOx Pharma Artificial Blood Substitute Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. NuvOx Pharma Artificial Blood Substitute Product Portfolio Table 63. NuvOx Pharma Recent Development Table 64. North America Artificial Blood Substitute Revenue by Type (2021-2026) & (US$ Million) Table 65. North America Artificial Blood Substitute Revenue by Type (2027-2032) & (US$ Million) Table 66. North America Artificial Blood Substitute Revenue by Application (2021-2026) & (US$ Million) Table 67. North America Artificial Blood Substitute Revenue by Application (2027-2032) & (US$ Million) Table 68. North America Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 69. North America Artificial Blood Substitute Revenue by Country (2021-2026) & (US$ Million) Table 70. North America Artificial Blood Substitute Revenue by Country (US$ Million) & (2027-2032) Table 71. Europe Artificial Blood Substitute Revenue by Type (2021-2026) & (US$ Million) Table 72. Europe Artificial Blood Substitute Revenue by Type (2027-2032) & (US$ Million) Table 73. Europe Artificial Blood Substitute Revenue by Application (2021-2026) & (US$ Million) Table 74. Europe Artificial Blood Substitute Revenue by Application (2027-2032) & (US$ Million) Table 75. Europe Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. Europe Artificial Blood Substitute Revenue by Country (2021-2026) & (US$ Million) Table 77. Europe Artificial Blood Substitute Revenue by Country (US$ Million) & (2027-2032) Table 78. China Artificial Blood Substitute Revenue by Type (2021-2026) & (US$ Million) Table 79. China Artificial Blood Substitute Revenue by Type (2027-2032) & (US$ Million) Table 80. China Artificial Blood Substitute Revenue by Application (2021-2026) & (US$ Million) Table 81. China Artificial Blood Substitute Revenue by Application (2027-2032) & (US$ Million) Table 82. Asia Artificial Blood Substitute Revenue by Type (2021-2026) & (US$ Million) Table 83. Asia Artificial Blood Substitute Revenue by Type (2027-2032) & (US$ Million) Table 84. Asia Artificial Blood Substitute Revenue by Application (2021-2026) & (US$ Million) Table 85. Asia Artificial Blood Substitute Revenue by Application (2027-2032) & (US$ Million) Table 86. Asia Artificial Blood Substitute Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 87. Asia Artificial Blood Substitute Revenue by Region (US$ Million) & (2021-2026) Table 88. Asia Artificial Blood Substitute Revenue by Region (US$ Million) & (2027-2032) Table 89. SAMEA Artificial Blood Substitute Revenue by Type (2021-2026) & (US$ Million) Table 90. SAMEA Artificial Blood Substitute Revenue by Type (2027-2032) & (US$ Million) Table 91. SAMEA Artificial Blood Substitute Revenue by Application (2021-2026) & (US$ Million) Table 92. SAMEA Artificial Blood Substitute Revenue by Application (2027-2032) & (US$ Million) Table 93. SAMEA Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. SAMEA Artificial Blood Substitute Revenue by Country (2021-2026) & (US$ Million) Table 95. SAMEA Artificial Blood Substitute Revenue by Country (US$ Million) & (2027-2032) Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Artificial Blood Substitute Image Figure 2. Global Artificial Blood Substitute Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Artificial Blood Substitute Market Size Share 2021 VS 2025 VS 2032 Figure 4. Perfluorocarbon-based Oxygen Carrier (PFBOC) Image Figure 5. Hemoglobin-based Oxygen Carrier (HBOC) Image Figure 6. Global Artificial Blood Substitute Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Artificial Blood Substitute Market Size Share 2021 VS 2025 VS 2032 Figure 8. Military Image Figure 9. Civil Image Figure 10. Global Artificial Blood Substitute Market Size (US$ Million) & (2021-2032) Figure 11. Global Artificial Blood Substitute Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Artificial Blood Substitute Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Artificial Blood Substitute Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Artificial Blood Substitute Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Artificial Blood Substitute Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Artificial Blood Substitute Revenue Market Share by Type (2021-2032) Figure 18. Global Artificial Blood Substitute Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Artificial Blood Substitute Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Artificial Blood Substitute Revenue Market Share by Application (2021-2032) Figure 21. North America Artificial Blood Substitute Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Artificial Blood Substitute Revenue Share by Type (2021-2032) Figure 23. North America Artificial Blood Substitute Revenue Share by Application (2021-2032) Figure 24. North America Artificial Blood Substitute Revenue Share by Country (2021-2032) Figure 25. United States Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Artificial Blood Substitute Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Artificial Blood Substitute Revenue Share by Type (2021-2032) Figure 30. Europe Artificial Blood Substitute Revenue Share by Application (2021-2032) Figure 31. Europe Artificial Blood Substitute Revenue Share by Country (2021-2032) Figure 32. Germany Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Artificial Blood Substitute Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Artificial Blood Substitute Revenue Share by Type (2021-2032) Figure 42. China Artificial Blood Substitute Revenue Share by Application (2021-2032) Figure 43. Asia Artificial Blood Substitute Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Artificial Blood Substitute Revenue Share by Type (2021-2032) Figure 45. Asia Artificial Blood Substitute Revenue Share by Application (2021-2032) Figure 46. Asia Artificial Blood Substitute Revenue Share by Region (2021-2032) Figure 47. Japan Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Artificial Blood Substitute Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Artificial Blood Substitute Revenue Share by Type (2021-2032) Figure 55. SAMEA Artificial Blood Substitute Revenue Share by Application (2021-2032) Figure 56. SAMEA Artificial Blood Substitute Revenue Share by Country (2021-2032) Figure 57. Brazil Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Artificial Blood Substitute Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Perfluorocarbon-based Oxygen Carrier (PFBOC)
  • Hemoglobin-based Oxygen Carrier (HBOC)
Applications
  • Military
  • Civil
Companies covered
  • Aurum Biosciences Ltd.
  • HEMARINA SA
  • HbO2 Therapeutics
  • KaloCyte Inc.
  • SpheriTech Ltd.
  • NuvOx Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Artificial Blood Substitute Market by Type
  3. 1.2.1 Global Artificial Blood Substitute Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Perfluorocarbon-based Oxygen Carrier (PFBOC)
  5. 1.2.3 Hemoglobin-based Oxygen Carrier (HBOC)
  6. 1.3 Artificial Blood Substitute Market by Application
  7. 1.3.1 Global Artificial Blood Substitute Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Military
  9. 1.3.3 Civil
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Artificial Blood Substitute Market Dynamics
  1. 2.1 Artificial Blood Substitute Industry Trends
  2. 2.2 Artificial Blood Substitute Industry Drivers
  3. 2.3 Artificial Blood Substitute Industry Opportunities and Challenges
  4. 2.4 Artificial Blood Substitute Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Artificial Blood Substitute Market Perspective (2021-2032)
  2. 3.2 Global Artificial Blood Substitute Growth Trends by Region
  3. 3.2.1 Global Artificial Blood Substitute Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Artificial Blood Substitute Market Size by Region (2021-2026)
  5. 3.2.3 Global Artificial Blood Substitute Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Artificial Blood Substitute Revenue by Players
  2. 4.1.1 Global Artificial Blood Substitute Revenue by Players (2021-2026)
  3. 4.1.2 Global Artificial Blood Substitute Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Artificial Blood Substitute Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Artificial Blood Substitute Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Artificial Blood Substitute Key Players Headquarters & Area Served
  7. 4.4 Global Artificial Blood Substitute Players, Product Type & Application
  8. 4.5 Global Artificial Blood Substitute Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Artificial Blood Substitute Market CR5 and HHI
  11. 4.6.3 2025 Artificial Blood Substitute Tier 1, Tier 2, and Tier 3
5 Artificial Blood Substitute Market Size by Type
  1. 5.1 Global Artificial Blood Substitute Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Artificial Blood Substitute Revenue by Type (2021-2032)
  3. 5.3 Global Artificial Blood Substitute Revenue Market Share by Type (2021-2032)
6 Artificial Blood Substitute Market Size by Application
  1. 6.1 Global Artificial Blood Substitute Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Artificial Blood Substitute Revenue by Application (2021-2032)
  3. 6.3 Global Artificial Blood Substitute Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Aurum Biosciences Ltd.
  2. 7.1.1 Aurum Biosciences Ltd. Company Information
  3. 7.1.2 Aurum Biosciences Ltd. Business Overview
  4. 7.1.3 Aurum Biosciences Ltd. Artificial Blood Substitute Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Aurum Biosciences Ltd. Artificial Blood Substitute Product Portfolio
  6. 7.1.5 Aurum Biosciences Ltd. Recent Developments
  7. 7.2 HEMARINA SA
  8. 7.2.1 HEMARINA SA Company Information
  9. 7.2.2 HEMARINA SA Business Overview
  10. 7.2.3 HEMARINA SA Artificial Blood Substitute Revenue and Gross Margin (2021-2026)
  11. 7.2.4 HEMARINA SA Artificial Blood Substitute Product Portfolio
  12. 7.2.5 HEMARINA SA Recent Developments
  13. 7.3 HbO2 Therapeutics
  14. 7.3.1 HbO2 Therapeutics Company Information
  15. 7.3.2 HbO2 Therapeutics Business Overview
  16. 7.3.3 HbO2 Therapeutics Artificial Blood Substitute Revenue and Gross Margin (2021-2026)
  17. 7.3.4 HbO2 Therapeutics Artificial Blood Substitute Product Portfolio
  18. 7.3.5 HbO2 Therapeutics Recent Developments
  19. 7.4 KaloCyte Inc.
  20. 7.4.1 KaloCyte Inc. Company Information
  21. 7.4.2 KaloCyte Inc. Business Overview
  22. 7.4.3 KaloCyte Inc. Artificial Blood Substitute Revenue and Gross Margin (2021-2026)
  23. 7.4.4 KaloCyte Inc. Artificial Blood Substitute Product Portfolio
  24. 7.4.5 KaloCyte Inc. Recent Developments
  25. 7.5 SpheriTech Ltd.
  26. 7.5.1 SpheriTech Ltd. Company Information
  27. 7.5.2 SpheriTech Ltd. Business Overview
  28. 7.5.3 SpheriTech Ltd. Artificial Blood Substitute Revenue and Gross Margin (2021-2026)
  29. 7.5.4 SpheriTech Ltd. Artificial Blood Substitute Product Portfolio
  30. 7.5.5 SpheriTech Ltd. Recent Developments
  31. 7.6 NuvOx Pharma
  32. 7.6.1 NuvOx Pharma Company Information
  33. 7.6.2 NuvOx Pharma Business Overview
  34. 7.6.3 NuvOx Pharma Artificial Blood Substitute Revenue and Gross Margin (2021-2026)
  35. 7.6.4 NuvOx Pharma Artificial Blood Substitute Product Portfolio
  36. 7.6.5 NuvOx Pharma Recent Developments
8 North America
  1. 8.1 North America Artificial Blood Substitute Revenue (2021-2032)
  2. 8.2 North America Artificial Blood Substitute Revenue by Type (2021-2032)
  3. 8.2.1 North America Artificial Blood Substitute Revenue by Type (2021-2026)
  4. 8.2.2 North America Artificial Blood Substitute Revenue by Type (2027-2032)
  5. 8.3 North America Artificial Blood Substitute Revenue Share by Type (2021-2032)
  6. 8.4 North America Artificial Blood Substitute Revenue by Application (2021-2032)
  7. 8.4.1 North America Artificial Blood Substitute Revenue by Application (2021-2026)
  8. 8.4.2 North America Artificial Blood Substitute Revenue by Application (2027-2032)
  9. 8.5 North America Artificial Blood Substitute Revenue Share by Application (2021-2032)
  10. 8.6 North America Artificial Blood Substitute Revenue by Country
  11. 8.6.1 North America Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Artificial Blood Substitute Revenue by Country (2021-2026)
  13. 8.6.3 North America Artificial Blood Substitute Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Artificial Blood Substitute Revenue (2021-2032)
  2. 9.2 Europe Artificial Blood Substitute Revenue by Type (2021-2032)
  3. 9.2.1 Europe Artificial Blood Substitute Revenue by Type (2021-2026)
  4. 9.2.2 Europe Artificial Blood Substitute Revenue by Type (2027-2032)
  5. 9.3 Europe Artificial Blood Substitute Revenue Share by Type (2021-2032)
  6. 9.4 Europe Artificial Blood Substitute Revenue by Application (2021-2032)
  7. 9.4.1 Europe Artificial Blood Substitute Revenue by Application (2021-2026)
  8. 9.4.2 Europe Artificial Blood Substitute Revenue by Application (2027-2032)
  9. 9.5 Europe Artificial Blood Substitute Revenue Share by Application (2021-2032)
  10. 9.6 Europe Artificial Blood Substitute Revenue by Country
  11. 9.6.1 Europe Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Artificial Blood Substitute Revenue by Country (2021-2026)
  13. 9.6.3 Europe Artificial Blood Substitute Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Artificial Blood Substitute Revenue (2021-2032)
  2. 10.2 China Artificial Blood Substitute Revenue by Type (2021-2032)
  3. 10.2.1 China Artificial Blood Substitute Revenue by Type (2021-2026)
  4. 10.2.2 China Artificial Blood Substitute Revenue by Type (2027-2032)
  5. 10.3 China Artificial Blood Substitute Revenue Share by Type (2021-2032)
  6. 10.4 China Artificial Blood Substitute Revenue by Application (2021-2032)
  7. 10.4.1 China Artificial Blood Substitute Revenue by Application (2021-2026)
  8. 10.4.2 China Artificial Blood Substitute Revenue by Application (2027-2032)
  9. 10.5 China Artificial Blood Substitute Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Artificial Blood Substitute Revenue (2021-2032)
  2. 11.2 Asia Artificial Blood Substitute Revenue by Type (2021-2032)
  3. 11.2.1 Asia Artificial Blood Substitute Revenue by Type (2021-2026)
  4. 11.2.2 Asia Artificial Blood Substitute Revenue by Type (2027-2032)
  5. 11.3 Asia Artificial Blood Substitute Revenue Share by Type (2021-2032)
  6. 11.4 Asia Artificial Blood Substitute Revenue by Application (2021-2032)
  7. 11.4.1 Asia Artificial Blood Substitute Revenue by Application (2021-2026)
  8. 11.4.2 Asia Artificial Blood Substitute Revenue by Application (2027-2032)
  9. 11.5 Asia Artificial Blood Substitute Revenue Share by Application (2021-2032)
  10. 11.6 Asia Artificial Blood Substitute Revenue by Country
  11. 11.6.1 Asia Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Artificial Blood Substitute Revenue by Country (2021-2026)
  13. 11.6.3 Asia Artificial Blood Substitute Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Artificial Blood Substitute Revenue (2021-2032)
  2. 12.2 SAMEA Artificial Blood Substitute Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Artificial Blood Substitute Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Artificial Blood Substitute Revenue by Type (2027-2032)
  5. 12.3 SAMEA Artificial Blood Substitute Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Artificial Blood Substitute Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Artificial Blood Substitute Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Artificial Blood Substitute Revenue by Application (2027-2032)
  9. 12.5 SAMEA Artificial Blood Substitute Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Artificial Blood Substitute Revenue by Country
  11. 12.6.1 SAMEA Artificial Blood Substitute Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Artificial Blood Substitute Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Artificial Blood Substitute Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst